Rulicent 10 mg (Tablet)
Unit Price: ৳ 300.00 (2 x 7: ৳ 4,200.00)
Strip Price: ৳ 2,100.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ruxolitinib oral |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of myelofibrosis in adults
- Treatment of polycythemia vera in adults
- Treatment of acute graft-versus-host disease in adult and pediatric patients
- Treatment of steroid-refractory acute graft-versus host disease in adult and pediatric patients
Pharmacology
- Inhibition of Janus Associated Kinases (JAKs) JAK1 and JAK2
- Modulation of gene expression
- Prevention of splenomegaly
- Reduction of JAK2V617F mutant cells in the spleen
- Decreased circulating inflammatory cytokines
Absorption
- Rapid absorption after oral administration
- Maximal plasma concentration achieved within 1 to 2 hours post-dose
- Estimated to be at least 95% orally absorbed
Distribution
- Mean volume of distribution at steady-state is 72 L in myelofibrosis patients
Half-life
- Mean half-life of approximately 5.8 hours
- Elimination half-life of approximately 3 hours
Plasma protein binding
- 97%, mostly to albumin
Metabolism
- Metabolized by CYP3A4 and to a lesser extent by CYP2C9
Excretion
- Elimination predominately through metabolism
- 74% excreted in urine
Dosage
- Starting dose based on platelet count
- Dose titration based on safety and efficacy
Administration
- Oral administration with or without food
- Not to take additional dose if missed
Interaction
- Contraindicated with fluconazole greater than 200 mg daily
- Increased exposure with strong CYP3A4 inhibitors
- No dose adjustment recommended with strong CYP3A4 inducers
Contraindications
- Hypersensitivity to Ruxolitinib or its components
Side Effects
- Thrombocytopenia, anemia, neutropenia
- Risk of infection, bruising, dizziness, headache
- Symptom exacerbation after discontinuation
- Non-melanoma skin cancer
Pregnancy & Lactation
- No adequate and well-controlled studies
- Discontinuation of breastfeeding during treatment
Precautions & Warnings
- Management of thrombocytopenia, anemia, neutropenia
- Observation for signs and symptoms of infection
- Evaluation for tuberculosis risk factors
- Monitoring and treatment for lipid parameter elevations
- Safe and effective use in pediatric patients not established
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
Overdose Effects
- No known antidote
- Increased myelosuppression with higher than recommended repeat doses
- Appropriate supportive treatment required
Therapeutic Class
- Pyrrolopyrimidines
Storage Conditions
- Store below 30°C in a dry place, away from sunlight